Primaquine for vivax malaria in G6PD-intermediate or deficient adults
Part of Blood & lymphatic, Genetic & congenital, Hormones & metabolism, Infections clinical trials.
This trial tests how well the drug primaquine works for people with vivax malaria who have intermediate or low levels of an enzyme called G6PD. It aims to find safe and effective treatment options for this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed vivax malaria infection (and no other type of malaria).
- Your G6PD level is intermediate (30% to less than 70% of normal) or deficient (30% or less of normal).
- You currently have a fever (temperature 37.5°C or higher) or have had a fever in the last 48 hours.
- You are 18 years old or older.
- Your hemoglobin level (a measure of red blood cells) is at least 8 g/dL.
- You live in the study area and are willing to be monitored for 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a revised dose of a medicine called tafenoquine to more effectively cure vivax malaria (a type of malaria that can come back). It is for people with normal G6PD enzyme levels and a current fever from vivax malaria.
This trial tests whether adding the drug tafenoquine to standard malaria treatment can prevent the return of P. vivax malaria. It is for adults who have a normal G6PD enzyme level and are healthy enough to participate.
This trial tests whether a shorter course of primaquine can effectively prevent relapses of vivax malaria. It aims to make treatment easier and safer for patients.
This study compares two medicines (tafenoquine and primaquine) taken with chloroquine to treat P. vivax malaria. It aims to see which is safer and works better in Indian participants aged 2 to 64.
This study tests how well a malaria treatment plan works for people with P. vivax malaria who don’t have another malaria type at the same time. It aims to see whether adding or using different medicines (ACT vs chloroquine with tafenoquine) helps clear infection and prevent return of disease.
This study measures how a medicine called an 8-aminoquinoline passes into breast milk after birth, to help prevent malaria in new mothers. If you and your baby have normal G6PD levels and you plan to exclusively breastfeed, this trial may be for you.
Hear when a new Vivax Malaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.